Antiplatelet resistance and thromboembolic complications in neurointerventional procedures

Frontiers in Neurology

Volumn DEC, Issue , 2011, Pages

  Oxley, Thomas J ^a   Dowling, Richard J ^a   Mitchell, Peter J ^a   Davis, Stephen ^a   Yan, Bernard ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Antiplatelet resistance; Aspirin; Clopidogrel; Endovascular; Neurointervention; Thromboembolism

Indexed keywords

EID: 84866234089     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2011.00083     Document Type: Article

References (71)

1. Abou-Chebl, A. (2011). Intracranial stenting with wingspan: still awaiting a safe landing. Stroke 42, 1809-1811.
2. Alberts, M. J. (2010). Platelet function testing for aspirin resistance is reasonable to do: yes! Stroke 41, 2400-2401.
3. Angiolillo, D. J., Fernandez-Ortiz, A., Bernardo, E., Ramírez, C., Barrera-Ramirez, C., Sabaté, M., Hernández, R., Moreno, R., Escaned, J., Alfonso, E, Banuelos, C., Costa, M. A., Bass, T. A., and Macaya, C. (2005). Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. ThrombRes. 115, 101-108.
4. Beigel, R., Hod, H., Fefer, P., Asher, E., Novikov, I., Shenkman, B., Savion, N., Varon, D., and Matetzky, S. (2011). Relation of aspirin failure to clinical outcome and to platelet response to aspirin in patients with acute myocardial infarction. Am. J. Cardiol. 107, 339-342.
5. Bennett, D., Yan, B., Macgregor, L., Eccleston, D., and Davis, S. M. (2008). A pilot study of resistance to aspirin in stroke patients. J. Clin. Neurosci. 15, 1204-1209.
6. Brooks, N. P., Turk, A. S., Niemann, D. B., Aagaard-Kienitz, B., Pulfer, K., and Cook, T. (2008). Frequency of thromboembolic events associated with endovascular aneurysm treatment: retrospective case series. J. Neurosurg. 108, 1095-1100.
7. Brott, T. G., Hobson, R. W., Howard, G., Roubin, G. S., Clark, W. M., Brooks, W., Mackey, A., Hill, M. D., Leim-gruber, P. P., Sheffet, A. J., Howard, V. J., Moore, W. S., Voeks, J. H., Hopkins, L. N., Cutlip, D. E., Cohen, D. J., Popma, J. J., Ferguson, R. D., Cohen, S. N., Blackshear, J. L., Silver, F. L., Mohr, J. P., Lal, B. K., Meschia, J. E, and CREST Investigators. (2010). Stenting versus endarterectomy for treatment of carotid-artery stenosis. N. Engl. J. Med. 363, 11-23.
8. Caplain, H., Donat, F., Gaud, C., and Necciari, J. (1999). Pharmacokinet-ics of clopidogrel. Semin. Thromb. Hemost. 25(Suppl. 2), 25-28.
9. Chimowitz, M. I., Lynn, M. J., Howlett-Smith, H., Stern, B. J., Hertzberg, V. S., Frankel, M. R., Levine, S. R., Chaturvedi, S., Kasner, S. E., Benesch, C. G., Sila, C. A., Jovin, T. G., Romano, J. G., and Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. (2005). Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N. Engl. J. Med. 352, 1305-1316.
10. Christiaens, L., Ragot, S., Mergy, J., Allal, J., and Macchi, L. (2008). Major clinical vascular events and aspirin-resistance status as determined by thePFA-100 method among patients with stable coronary artery disease: a prospective study. Blood Coagul. Fibrinolysis 19,235-239.
11. Collaboration, C. S. T. (2010). Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. Lancet 376,1062-1073.
12. Collet, J.-P., Hulot, J.-S., Pena, A., Vil-lar d, E., Esteve, J.-B., Silvain, J., Payot, L., Brugier, D., Cayla, G., Beygui, E, Bensimon, G., Funck-Brentano, C., and Montalescot, G. (2009). Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373, 309-317.
13. COMMIT Collaborative Group. (2005). Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366, 1607-1621.
14. Eikelboom, J. W., Hirsh, J., Weitz, J. I., Johnston, M., Yi, Q., and Yusuf, S. (2002). Aspirin-resistant throm-boxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105,1650-1655.
15. Farid, N. A., Kurihara, A., and Wrighton, S. A. (2010). Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J. Clin. Pharmacol. 50, 126-142.
16. Fiorella, D. J., Turk, A. S., Levy, E. I., Pride, G. L., Woo, H. H., Albuquerque, E C., Welch, B. G., Niemann, D. B., Aagaard-Kienitz, B., Rasmussen, P. A., Hopkins, L. N., Masaryk, T. J., and McDougall, C. G. (2011). U.S. Wingspan Registry: 12-month follow-up results. Stroke 42, 1976-1981.
17. Fukuoka, T., Furuya, D., Takeda, H., Dembo, T., Nagoya, H., Kato, Y., Deguchi, I., Maruyama, H., Hori-uchi, Y., and Tanahashi, N. (2011) Evaluation of clopidogrel resistance in ischemic stroke patients. Intern. Med. 50,31-35.
18. Gerlach, R., Beck, J., Setzer, M., Vat-ter, H., Berkefeld, J., Mesnil De Rochemont Du, R., Raabe, A., and Seifert, V. (2007) Treatment related morbidity of unruptured intracranial aneurysms: results of a prospective single centre series with an interdisciplinary approach over a 6 year period (1999-2005). J. Neurol. Neurosurg. Psychiatry 78, 864-871.
19. Gori, A. M., Marcucci, R., Migliorini, A., Valenti, R., Moschi, G., Panic-cia, R., Buonamici, P., Gensini, G. F., Vergara, R., Abbate, R., and Antoni-ucci, D. (2008). Incidence and clinical impact of dual nonresponsive-ness to aspirin and clopidogrel in patients with drug-eluting stents. J. Am. Coll. Cardiol. 52, 734-739.
20. Gupta, R., Jovin, T. G., Yavagal, D., and Abou-Chebl, A. (2010). Carotid endarterectomy vs. carotid stenting: fairly comparable or unfairly compared? Front. Neurol. 1:14. doi:10.3389/fneur.2010.00014
21. Gurbel, P. A., Bliden, K. P., Hiatt, B. L., and O'Connor, C. M. (2003). Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107, 2908-2913.
22. Hagihara, K., Kazui, M., Kurihara, A., Yoshiike, M., Honda, K., Okazaki, O., Farid, N. A., and Ikeda, T. (2009). A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab. Dispos. 37, 2145-2152.
23. Hankey, G. J., and Eikelboom, J. W. (2006). Aspirin resistance. Lancet 367, 606-617.
24. Harrison, P. (2005). Platelet function analysis. Blood Rev. 19,111-123.
25. Harrison, P., Segal, H., Blasbery, K., Furtado, C., Silver, L., and Roth-well, P. M. (2005). Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 36,1001-1005.
26. Hart, R. G., Leonard, A. D., Talbert, R. L., Pearce, L. A., Cornell, E., Bovill, E., and Feinberg, W M. (2003). Aspirin dosage and thromboxane synthesis in patients with vascular disease. Pharmacotherapy 23, 579-584
27. Holloway, R. G., Benesch, C. G., Rahilly, C. R., and Courtright, C. E. (1999). A systematic review of cost-effectiveness research of stroke evaluation and treatment. Stroke 30, 1340-1349.
28. Hovens, M. M. C., Snoep, J. D., Eiken-boom, J. C. J., van der Bom, J. G., Mertens, B. J. A., and Huisman, M. V. (2007). Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am. HeartJ. 153, 175-181.
29. *3 alle-les attenuate response to clopido-grel similarly in East Asian patients undergoing elective percutaneous coronary intervention. Thromb Res. 127, 23-28.
30. ICSS Investigators. (2010). Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. Lancet 375, 985-997.
31. Im, S.-H., Han, M., Kwon, O.-K., Kwon, B., Kim, S., Kim, J., and Oh, C. W. (2008). Endovascular coil emboliza-tion of 435 small asymptomatic unruptured intracranial aneurysms: procedural morbidity and patient outcome. AJNR Am. J. Neuroradiol. 30, 79-84.
32. Jakubowski, J. A., Li, Y. G., Small, D. S., Payne, C. D., Tomlin, M. E., Luo, J., and Winters, K. J. (2010). A comparison of theVerifyNowP2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis. J. Cardiovasc. Pharmacol. 56, 29-37.
33. Jakubowski, J. A., Payne, C. D., Li, Y. G., Brandt, J. T., Small, D. S., Farid, N. A., Salazar, D. E., and Winters, K. J. (2008). The use of the Veri-fyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost. 99,409-415.
34. Jiang, W.-J., Yu, W., Du, B., Gao, F., and Cui, L.-Y. (2011). Outcome of patients with >=70% symptomatic intracranial stenosis after wingspan stenting. Stroke 42, 1971-1975.
35. Kazui, M., Nishiya, Y., Ishizuka, T., Hag-ihara, K., Farid, N. A., Okazaki, O., Ikeda, T., and Kurihara, A. (2010). Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos. 38, 92-99.
36. Klisch, J., Turk, A., Turner, R., Woo, H. H., and Fiorella, D. (2011). Very late thrombosis of flow-diverting constructs after the treatment of large fusiform posterior circulation aneurysms. AJNR Am. J. Neuroradiol. 32,627-632.
37. Krasopoulos, G., Brister, S. J., Beat-tie, W S., and Buchanan, M. R. (2008). Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336, 195-198.
38. L'Allier, P. L., Ducrocq, G., Pranno, N., Noble, S., Ibrahim, R., Gré-goire, J. C., Azzari, F., Nozza, A., Berry, C., Doucet, S., Labarthe, B., Théroux, P., Tardif, J. C., and PRE-PAIR Study Investigators. (2008). Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study. J. Am. Coll Cardiol. 51, 1066-1072.
39. Lanterna, L. A., Tredici, G., Dim-itrov, B. D., and Biroli, F. (2004). Treatment of unruptured cerebral aneurysms by embolization with guglielmi detachable coils: case-fatality, morbidity, and effectiveness in preventing bleeding - a systematic review of the literature. Neuro-surgery 55, 767-778.
40. Lau, W C. (2004). Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109, 166-171.
41. Layton, K., Cloft, H., Gray, L., Lewis, D., and Kallmes, D. (2007). Balloon-assisted coiling of intracra nial aneurysms: evaluation of local thrombus formation and symptomatic thromboembolic complications. AJNR Am. J. Neuroradiol. 28, 1172-1175.
42. Lee, D., Arat, A., Morsi, H., Shaltoni, H., Harris, J., and Mawad, M. (2008). Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience. AJNR Am. J. Neuroradiol. 29, 1389-1394.
43. Lordkipanidzé, M., Pharand, C., Scham-paert, E., Turgeon, J., Palisaitis, D. A., and Diodati, J. G. (2007). A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur. Heart J. 28, 1702-1708.
44. Maeda, A., Ando, H., Asai, T., Ishiguro, H., Umemoto, N., Ohta, M., Mor-ishima, M., Sumida, A., Kobayashi, T., Hosohata, K., Ushijima, K., and Fujimura, A. (2011). Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine. Clin. Pharmacol Ther. 89,229-233.
45. Malinin, A., Pokov, A., Spergling, M., Defranco, A., Schwartz, K., Schwartz, D., Mahmud, E., Atar, D., and Serebruany, V. (2007). Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the verify thrombosis risk assessment (VERITAS) study. Thromb Res. 119, 277-284.
46. Malinin, A., Pokov, A., Swaim, L., Kotob, M., and Serebruany, V. (2006). Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp. Clin. Pharmacol. 28, 315-322.
47. Mansour, K., Taher, A. T., Musal-lam, K. M., and Alam, S. (2009). Aspirin resistance. Adv. Hematol. 2009,937352.
48. Maruyama, H., Takeda, H., Dembo, T., Nagoya, H., Kato, Y., Fukuoka, T., Deguchi, I., Horiuchi, Y., and Tana-hashi, N. (2011). Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic stroke or carotid artery stenting using the VerifyNow P2Y12 Assay. Intern. Med. 50, 695-698.
49. Mas, J.-L., Chatellier, G., Beyssen, B., Branchereau, A., Moulin, T., Bec-quemin, J.-P., Larrue, V., Lièvre, M., Leys, D., Bonneville, J. F., Watelet, J., Pruvo, J. P., Albucher, J. F., Vigu-ier, A., Piquet, P., Garnier, P., Viader, E, Touze, E., Giroud, M., Hosseini, H., Pillet, J. C., Favrole, P., Neau, J. P., Ducrocq, X., and EVA-3S Investigators. (2006). Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N. Engl. J. Med. 355, 1660-1671.
50. Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E., and Saba-tine, M. S. (2009). Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362.
51. Mocco, J., Fargen, K. M., Albuquerque, E C, Bendok, B. R., Boulos, A. S., Carpenter, J. S., Fiorella, D. J., Hoh, B. L., Howington, J. U., Liebman, K. M., Natarajan, S. K., Rai, A. T., Rodriguez-Mercado, R., Siddiqui, A. H., Snyder, K. V., Veznedaroglu, E., Hopkins, L.N., and Levy, E. I. (2011). Delayed thrombosis or stenosis following enterprise-assisted stent-coiling: is it safe? Midterm results of the interstate collaboration of enterprise stent coiling. Neurosurgery 69, 908-913.
52. Moret, J., Cognard, C., Weill, A., Cas-taings, L.,andRey,A. (1997). Reconstruction technic in the treatment of wide-neck intracranial aneurysms. Long-term angiographic and clinical results. Apropos of 56 cases. J. Neuroradiol. 24, 30-44.
53. Nelson, P. K., Lylyk, P., Szikora, I., Wet-zel, S. G., Wanke, I., and Fiorella, D. (2011). The pipeline emboliza tion device for the intracranial treat ment of aneurysms trial. AJNR Am. J. Neuroradiol. 32, 34-40.
54. Nicholson, N. S., Panzer-Knodle, S. G., Haas, N. F., Taite, B. B., Szalony, J. A., Page, J. D., Feigen, L. P., Lansky, D. M., and Salyers, A. K.( 1998). Assessment of platelet function assays. Am. Heart J. 135, S170-S178.
55. Nielsen, H. L., Kristensen, S. D., Thyge-sen, S. S., Mortensen, J., Pedersen, S. B., Grove, E. L., and Hvas, A. M. (2008). Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. Thromb Res. 123, 267-273.
56. O'Donoghue, M. L., Braunwald, E., Antman, E. M., Murphy, S. A., Bates, E. R., Rozenman, Y., Michelson, A. D., Hautvast, R. W., Ver Lee, P. N., Close, S. L., Shen, L., Mega, J. L., Sabatine, M. S., and Wiviott, S. D. (2009). Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analy sis of two randomised trials. Lancet 374, 989-997.
57. Ozben, S., Ozben, B., Tanrikulu, A. M., Ozer, F., and Ozben, T. (2011). Aspirin resistance in patients with acute ischemic stroke. J. Neurol. 258, 1979-1986.
58. Pandya, D. J., Fitzsimmons, B. F. M., Wolfe, T. J., Hussain, S. I., Lynch, J. R., Ortega-Gutierrez, S., and Zai-dat, O. O. (2010). Measurement of antiplatelet inhibition during neurointerventional procedures: the effect of antithrombotic duration and loading dose. J. Neuroimaging 20, 64-69.
59. Paré, G., Mehta, S. R., Yusuf, S., Anand, S. S., Connolly, S. J., Hirsh, J., Simon-sen, K., Bhatt, D. L., Fox, K. A., and Eikelboom, J. W (2010). Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med. 363,1704-1714.
60. Popma, J. J., Berger, P., Ohman, E. M., Harrington, R. A., Grines, C., and Weitz, J. I. (2004) Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(Suppl. 3), 576S-599S.
61. Prabhakaran, S., Wells, K. R., Lee, V. H., Flaherty, C. A., and Lopes, D. K. (2008). Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am. J. Neuroradiol. 29, 281-285.
62. Sabatine, M. S., Cannon, C. P., Gibson, C. M., López-Sendón, J. L., Mon-talescot, G., Theroux, P., Claeys, M. J., Cools, F., Hill, K. A., Skene, A. M., McCabe, C. H., Braunwald, E., and CLARITY-TIMI 28 Investigators. (2005). Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl. J. Med. 352,1179-1189.
63. Sandercock, P. A. G., Counsell, C., Gubitz, G. J., and Tseng, M.-C. (2008). Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst. Rev. CD000029.
64. Savi, P., Pereillo, J. M., Uzabiaga, M. F., Combalbert, J., Picard, C., Maffrand, J. P., Pascal, M., and Herbert, J. M. (2000). Identification and biological activity of the active metabolite of clopidogrel. Thromb. Haemost. 84, 891-896.
65. Shen, H., Herzog, W., Drolet, M., Pakyz, R., Newcomer, S., Sack, P., Karon, H., Ryan, K. A., Zhao, Y., Shi, X., Mitchell, B. D., and Shuldiner, A. R. (2009). Aspirin Resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study). Am. J. Cardiol. 104, 606-612.
66. Shuldiner, A. R., O'Connell, J. R., Bliden, K. P., Gandhi, A., Ryan, K., Horenstein, R. B., Damcott, C. M., Pakyz, R., Tantry, U. S., Gibson, Q., Pollin, T. I., Post, W., Parsa, A., Mitchell, B. D., Faraday, N., Herzog, W., and Gurbel, P. A. (2009). Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302, 849-857.
67. Sluzewski, M., van Rooij, W. J., Beute, G. N., and Nijssen, P. C. (2006). Balloon-assisted coil embolization of intracranial aneurysms: incidence, complications, and angiog-raphy results. J. Neurosurg. 105, 396-399.
68. SPACE Collaborative Group, Ringleb, P. A., Allenberg, J., Brückmann, H., Eckstein, H.-H., Fraedrich, G., Hart-mann, M., Hennerici, M., Jansen, O., Klein, G., Kunze, A., Marx, P., Niederkorn, K., Schmiedt, W., Solymosi, L., Stingele, R., Zeumer, H., and Hacke, W. (2006). 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 368, 1239-1247.
69. van Rooij, W. J., and Sluzewski, M. (2006). Procedural morbidity and mortality of elective coil treatment of unruptured intracranial aneurysms. AJNR Am. J. Neurora-diol. 27,1678-1680.
70. Walcott, B. P., Pisapia, J. M., Nahed, B. V., Kahle, K. T., and Ogilvy, C. S. (2011). Early experience with flow diverting endoluminal stents for the treatment of intracranial aneurysms. J. Clin. Neurosci. 18, 891-894.
71. Yamada, N., Cross, D., Pilgram, T., Moran, C., Derdeyn, C., and Dacey, R. (2007). Effect of antiplatelet therapy on thromboem-bolic complications of elective coil embolization of cerebral aneurysms. AJNR Am. J. Neuroradiol. 28, 1778-1782.